PPI Sequencing study

Study identifier:D9612L00104

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A study to Assess the effectiveness of Esomeprazole 40 mg once daily in subjects with continuing Gastroesophageal Reflux Disease (GORD) symptoms following treatment wit a previous full dose Proton Pump Inhibitor (PPI)

Medical condition

Gastro-oesophageal reflux disease

Phase

Phase 4

Healthy volunteers

No

Study drug

Esomeprazole

Sex

All

Actual Enrollment

100

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Sept 2006
Primary Completion Date: 01 May 2007
Study Completion Date: 01 May 2007

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria